Research programme: sustained release therapeutics - Labopharm/Meda Pharmaceuticals

Drug Profile

Research programme: sustained release therapeutics - Labopharm/Meda Pharmaceuticals

Alternative Names: DDS-2001

Latest Information Update: 10 Oct 2011

Price : $50

At a glance

  • Originator Labopharm
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 29 Nov 2004 This programme is still in active development
  • 08 Aug 2003 Labopharm has completed feasibility and formulation studies for DDS 2001
  • 11 Jul 2002 Preclinical trials in Undefined in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top